Efficacy of SPK-843, a Novel Polyene Antifungal, in Comparison with Amphotericin B, Liposomal Amphotericin B, and Micafungin against Murine Pulmonary Aspergillosis-Reference-Cited by-同舟云学术

Efficacy of SPK-843, a Novel Polyene Antifungal, in Comparison with Amphotericin B, Liposomal Amphotericin B, and Micafungin against Murine Pulmonary Aspergillosis

Published:2008-05 Issue:5 Volume:52 Page:1868-1870
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Kakeya Hiroshi¹,Miyazaki Yoshitsugu²,Senda Hisato³,Kobayashi Tsutomu¹,Seki Masafumi¹,Izumikawa Koichi¹,Yanagihara Kazunori¹,Yamamoto Yoshihiro¹,Tashiro Takayoshi¹,Kohno Shigeru¹

Affiliation:

1. Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

2. Department of Bioactive Molecules, National Institute of Infectious Disease, Tokyo, Japan

3. Kaken Pharmaceutical Co., Ltd., Kyoto, Japan

Abstract

ABSTRACT SPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01369-07

Reference12 articles.

1. Bruzzese, T., M. R. Galmozzi, V. M. Ferrari, P. Sala, and A. Bonabello. 2001. Comparative pharmacokinetics of three preparations of the new antifungal SPK-843. Chemotherapy47:387-395.

2. Bruzzese, T., M. R. Galmozzi, G. Buffa, P. Sala, and A. Bonabello. 2001. Pharmacokinetics in rats of N-dimethylaminoacetyl-partricin A 2-dimethylaminoethylamide diascorbate (SPK-843). Chemotherapy47:77-85.

3. Clemons, K. V., and D. A. Stevens. 2006. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med. Mycol.44:69-73.

4. Approved standard. Document M38-A. 2002

5. Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antifungals;Biochemical Pharmacology;2017-06

2. Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization;Frontiers in Microbiology;2017-05-16

3. Antifungals: Mechanism of Action and Drug Resistance;Advances in Experimental Medicine and Biology;2016

4. Insights in Antifungal Drug Discovery;Candida and Candidiasis;2014-04-09

5. Efficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosis;Journal of Infection and Chemotherapy;2014-02